Literature DB >> 35195606

Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan.

Kiyotsugu Iede, Terumasa Yamada, Masahiro Koh, Masami Ueda, Yujiro Tsuda, Shinsuke Nakashima, Katsuya Ohta, Tsukasa Tanida, Jin Matsuyama, Masakazu Ikenaga, Shusei Tominaga.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35195606     DOI: 10.1097/MPA.0000000000001942

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


× No keyword cloud information.
  2 in total

1.  Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer.

Authors:  Kiyotsugu Iede; Terumasa Yamada; Masami Ueda; Yujiro Tsuda; Shinsuke Nakashima; Katsuya Ohta; Tsukasa Tanida; Jin Matsuyama; Masakazu Ikenaga; Shusei Tominaga
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

2.  Efficacy of relative dose intensity of nab-paclitaxel for the short-term outcomes, survival, and quality of life in patients with advanced pancreatic cancer: a retrospective study.

Authors:  Lian Lian; Xiao-Ming Shen; Tie-Ao Huang; Da-Peng Li; Xian-Min Li; Shu-Guang Han; Xue-Fei Xu; Chun-Tao Ma; Chong Zhou
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.